Recombinant KRT17 antibody

Catalog No. ABIN7881373

The Rabbit Monoclonal anti-KRT17 antibody is suitable to detect KRT17 in samples from Human. It has been validated for IHC (p).

Quick Overview for Recombinant KRT17 antibody (ABIN7881373)

Target: KRT17 (Keratin 17 (KRT17))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This KRT17 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: KRT17-8346R

Product Details anti-KRT17 Antibody

Purpose: Recombinant Keratin 17 Antibody / Cytokeratin 17

Purification: Protein A/G affinity

Immunogen: A recombinant fragment of human KRT17 protein was used as the immunogen for the recombinant Keratin 17 antibody.

Isotype: IgG, kappa

Application Details

Application Notes: Optimal dilution of the recombinant Keratin 17 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the recombinant Keratin 17 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for KRT17

Target: KRT17 (Keratin 17 (KRT17))

Alternative Name: Keratin 17

Background: Cytokeratin 17 is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. It is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course.

UniProt: Q04695